NCT02767297View on ClinicalTrials.gov

Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Cystic Fibrosis
Interventions
DRUG

FDL169

Trial Locations (1)

BT9 6AD

Celerion, Belfast

All Listed Sponsors
lead

Flatley Discovery Lab LLC

OTHER

NCT02767297 - Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis | Biotech Hunter | Biotech Hunter